相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End
Amanda R. Wasylishen et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
The Role of MDM2 Amplification and Overexpression in Tumorigenesis
Jonathan D. Oliner et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
C. Gianna Hoffman-Luca et al.
CLINICAL CANCER RESEARCH (2015)
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors
Philipp Holzer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression
Shaomeng Wang et al.
CANCER RESEARCH (2014)
Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2-p53 Inhibitor in Clinical Development
Daqing Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development
Qingjie Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
A Potent Small-Molecule Inhibitor of the MDM2-p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice
Yujun Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors
Yujun Zhao et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
Binh Vu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Mark Wade et al.
NATURE REVIEWS CANCER (2013)
Structure-Based Design of Novel Inhibitors of the MDM2-p53 Interaction
Yosup Rew et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Ordering of the N-Terminus of Human MDM2 by Small Molecule Inhibitors
Klaus Michelsen et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
Isabelle Ray-Coquard et al.
LANCET ONCOLOGY (2012)
Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma
Joshua Weaver et al.
MODERN PATHOLOGY (2009)
Awakening guardian angels: drugging the p53 pathway
Christopher J. Brown et al.
NATURE REVIEWS CANCER (2009)
Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms
Joshua Weaver et al.
MODERN PATHOLOGY (2008)
The p53 family in differentiation and tumorigenesis
Thorsten Stiewe
NATURE REVIEWS CANCER (2007)
Regulating the p53 pathway:: in vitro hypotheses, in vivo veritas
Franck Toledo et al.
NATURE REVIEWS CANCER (2006)
Structure-based design of potent non-peptide MDM2 inhibitors
K Ding et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2005)
MDM2 is a central node in the p53 pathway: 12 years and counting
GL Bond et al.
CURRENT CANCER DRUG TARGETS (2005)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
GL Bond et al.
CELL (2004)
Mutational spectrum of p53 mutations in primary breast and ovarian tumors
A Feki et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2004)
Live or let die: The cell's response to p53
KH Vousden et al.
NATURE REVIEWS CANCER (2002)
MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis
G Ganguli et al.
EMBO JOURNAL (2000)
Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53
C García-Echeverría et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
MDM2 - master regulator of the p53 tumor suppressor protein
J Momand et al.
GENE (2000)
分享论文
